Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-12-10

FDA Approved: GALAFOLD — Supplemental Application (Amicus Therapeutics US, LLC)

View source ↗

Summary

The FDA approved a supplemental application for GALAFOLD (migalastat hydrochloride) to expand its labeling for Fabry disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GALAFOLD (MIGALASTAT HYDROCHLORIDE)

Snippet

SUPPL AP for GALAFOLD (MIGALASTAT HYDROCHLORIDE)